Overview: Allergy Cladosporium Herbarum TestIntroduction: The Allergy Cladosporium Herbarum Test detects IgE antibodies to Cladosporium herbarum mold, which may cause sneezing, coughing, or asthma in moldy environments. Following 2023 AAAAI guidelines, it uses an immunoassay for high sensitivity, aiding in confirming mold allergies. This test is critical for guiding avoidance strategies or immunotherapy, preventing allergic reactions, and improving outcomes in allergology.
Other Names: Allergy Cladosporium Assay, Cladosporium Herbarum IgE Test.
FDA Status: Laboratory-developed test (LDT) meeting allergology standards for diagnostic accuracy.
Historical Milestone: Mold allergy testing began in the 1970s with skin tests. Specific IgE immunoassays emerged in the 1980s, and by the 2000s, advanced assays improved specificity for mold allergens like Cladosporium, driven by improved protein detection methods.
Purpose: Diagnoses Cladosporium herbarum mold allergies, guides avoidance or immunotherapy, and monitors allergic responses in patients with respiratory or asthma symptoms triggered by mold exposure.
Test Parameters: 1. Cladosporium Herbarum IgE
Pretest Condition: No fasting required. Collect serum or saliva at any time, preferably during symptom onset or mold exposure. Report symptoms like sneezing, coughing, or asthma, and list medications like antihistamines or corticosteroids.
Specimen: 2-5 mL serum (SST) or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours to maintain sample integrity.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document respiratory symptoms, mold exposure history, or family history of allergies or asthma. Include current medications, especially antihistamines, corticosteroids, or bronchodilators, which may influence results.
Consent: Written consent required, explaining the tests purpose, diagnostic implications, and potential need for avoidance strategies or immunotherapy to manage mold allergies.
Procedural Considerations: Uses an immunoassay to measure Cladosporium-specific IgE. Results are available in 1-2 days, supporting rapid diagnosis. Performed in laboratories with strict quality controls.
Factors Affecting Result Accuracy: Antihistamines or corticosteroids may suppress IgE levels, causing false negatives. Hemolysis or improper storage can degrade samples. Testing during low mold exposure may reduce sensitivity, affecting result reliability.
Clinical Significance: Elevated Cladosporium-specific IgE confirms mold allergy, prompting avoidance (e.g., reducing mold exposure) or immunotherapy. Normal levels may require skin testing or clinical correlation to rule out allergy.
Specialist Consultation: Consult an allergist for result interpretation. A pulmonology referral is advised for asthma-related cases to manage respiratory symptoms effectively.
Additional Supporting Tests: Skin prick test, total IgE, or mold allergy panel to confirm Cladosporium allergy or identify cross-reactive molds like Alternaria.
Test Limitations: False negatives may occur with antihistamine use or low mold exposure. Cross-reactivity with other molds requires clinical correlation to ensure accurate diagnosis.
References: AAAAI Allergy Guidelines, 2023; Clinical and Translational Allergy, Denning DW, 2022.
